Prostate Cancer

Top Story

Guest Commentary: STAMPEDE trial provides exciting results, questions in prostate cancer treatment

Guest Commentary: STAMPEDE trial provides exciting results, questions in prostate cancer treatment
June 21, 2017

In this guest commentary, Terence Friedlander, MD, discusses the benefits associated with the addition of abiraterone acetate to standard treatment in patients with high-risk advanced prostate cancer and the challenges facing the community , following a presentation of the STAMPEDE trial delivered at the ASCO Annual Meeting by Nicholas James, BSc, MBBS, PhD, from Queen Elizabeth Hospital in Birmingham, United Kingdom . Friedlander is an assistant clinical professor at the division of hematology/oncology at UCSF’s Helen Diller Family Comprehensive Cancer Center .

Meeting NewsVideo

VIDEO: Results of LATITUDE trial reinforce long-hypothesized theory in prostate cancer treatment

June 21, 2017
CHICAGO — The results of the LATITUDE trial demonstrated that the addition of abiraterone acetate with prednisone to standard hormonal therapy led to a decreased…
Meeting NewsVideo

VIDEO: Immunotherapy agent induces response in prostate cancer

June 20, 2017
CHICAGO — The use of sipuleucel-T in patients with hormone-sensitive and castration-resistant prostate cancer demonstrated an increase in the proliferation of CD4…

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist, also will serve as…
CME

What's Hot in Melanoma? Highlights from the HemOnc Today Melanoma and Cutaneous Malignancies 2017 Meeting

This activity is supported by an educational grant from Merck & Co, Inc.

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the…
More »
Video
Meeting News

VIDEO: Results of LATITUDE trial reinforce long-hypothesized theory in prostate cancer treatment

June 21, 2017
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed…
More »
Meeting News

Guest Commentary: STAMPEDE trial provides exciting results, questions in prostate cancer treatment

June 21, 2017
In this guest commentary, Terence Friedlander, MD, discusses the benefits associated with the addition of

Meeting NewsVideo

VIDEO: Results of LATITUDE trial reinforce long-hypothesized theory in prostate cancer treatment

June 21, 2017
CHICAGO — The results of the LATITUDE trial demonstrated that the addition of abiraterone acetate with prednisone to standard hormonal therapy…

Meeting NewsVideo

VIDEO: Immunotherapy agent induces response in prostate cancer

June 20, 2017
CHICAGO — The use of sipuleucel-T in patients with hormone-sensitive and castration-resistant prostate cancer demonstrated an increase in the…

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist…

10 highlights from the ASCO Annual Meeting

June 16, 2017
This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.” …

In the Journals Plus

Men with prostate cancer willing to pay more for advanced biopsies

June 15, 2017
Men with prostate cancer paid up to $2,000 out of health savings accounts for magnetic resonance imaging–transrectal ultrasound…

Oral contraceptive use does not increase long-term cancer risk

June 14, 2017
Women who used oral contraceptives did not demonstrate increased long-term cancer risk, according to results of the Royal College of General…

Hypofractionated radiotherapy effective for localized prostate cancer

June 13, 2017
Men with localized prostate cancer who received radiation treatments over 4 weeks achieved comparable outcomes as those who received the standard…

Meeting NewsVideo

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

June 12, 2017
CHICAGO — Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology. The…

FDA News

FDA rejects Coherus application for proposed biosimilar to Neulasta

June 12, 2017
The FDA denied approval of Coherus BioSciences’ biologics license application for CHS-1701, a proposed biosimilar for pegfilgrastim. Like…

More Headlines »
Advertisement
Advertisement